Methods and compositions for targeting polyubiquitin
AssigneeGenentech, Inc.
InventorsNathaniel C. Gordon, Robert F. Kelley, Anh Pham
Life of this patent
Estimating the term…
Abstract
Anti-polyubiquitin monoclonal antibodies, and methods for using the antibodies, are provided.
Claims31
-68. (canceled)
A nucleic acid molecule that encodes an antibody that specifically binds to a first polyubiquitin comprising a first lysine linkage between a lysine residue of one ubiquitin molecule and the C-terminal glycine residue of another ubiquitin molecule, wherein the antibody does not specifically bind to a second polyubiquitin comprising a second lysine linkage between a second lysine residue of one ubiquitin molecule and the C-terminal glycine residue of another ubiquitin molecule, and wherein the first lysine linkage differs from the second lysine linkage.
A nucleic acid molecule that encodes an antibody that specifically binds lysine-48-linked polyubiquitin, wherein the antibody does not specifically bind monoubiquitin, wherein said antibody specifically binds lysine-48-linked polyubiquitin with high affinity but binds lysine-63-linked polyubiquitin with substantially reduced affinity or does not specifically bind lysine-63-linked polyubiquitin.
A nucleic acid molecule that encodes an antibody that specifically binds to lysine-63-linked polyubiquitin, wherein the antibody does not specifically bind to monoubiquitin, wherein said antibody specifically binds lysine-63-linked polyubiquitin with high affinity but binds lysine-48-linked polyubiquitin with substantially reduced affinity or does not specifically bind lysine-48-linked polyubiquitin.
An isolated antibody comprising a hypervariable (HVR)-H1, a HVR-H2, a HVR-H3, a HVR-L1, a HVR-L2, and a HVR-L3, wherein the HVR-H1 sequence is SEQ ID NO:
- 423, the HVR-H2 is SEQ ID NO:
- 492, the HVR-H3 is SEQ ID NO:
- 561, the HVR-L1 is SEQ ID NO:
- 79, the HVR-L2 is SEQ ID NO:
- 80, and the HVR-L3 is SEQ ID NO:
- 317.
Dependencies are inferred from the claim text.